판토프라졸 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "판토프라졸" in Korean language version.

refsWebsite

Global rank Korean rank

11nih.gov

4^th place

9doi.org

2^nd place

3^rd place

4semanticscholar.org

11^th place

310^th place

3fda.gov

447^th place

433^rd place

2drugs.com

399^th place

141^st place

2clincalc.com

3,912^th place

2,490^th place

1medicines.org.uk

3,823^rd place

2,321^st place

1ubc.ca

1,997^th place

1,227^th place

1books.google.com

3^rd place

9^th place

1chron.com

599^th place

2,980^th place

1web.archive.org

1^st place

books.google.com

Fischer J, Ganellin CR (2006). 《Analogue-based Drug Discovery》. John Wiley & Sons. 130쪽. ISBN 9783527607495.

chron.com

blog.chron.com

Ackerman T (2013년 7월 10일). “Acid reflux drugs may lead to heart disease, says Houston study”. 《Houston Chronicle》.

clincalc.com

“The Top 300 of 2020”. 《ClinCalc》. 2022년 10월 7일에 확인함.
“Pantoprazole - Drug Usage Statistics”. 《ClinCalc》. 2022년 10월 7일에 확인함.

doi.org

dx.doi.org

Richardson P, Hawkey CJ, Stack WA (September 1998). “Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders”. 《Drugs》 56 (3): 307–335. doi:10.2165/00003495-199856030-00002. PMID 9777309. S2CID 46962618.
Dammann HG, Fölsch UR, Hahn EG, von Kleist DH, Klör HU, Kirchner T, 외. (March 2000). “Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration”. 《Helicobacter》 5 (1): 41–51. doi:10.1046/j.1523-5378.2000.00006.x. PMID 10672051. S2CID 32184484.
Strand DS, Kim D, Peura DA (January 2017). “25 Years of Proton Pump Inhibitors: A Comprehensive Review”. 《Gut and Liver》 11 (1): 27–37. doi:10.5009/gnl15502. PMC 5221858. PMID 27840364.
Herzig SJ, Doughty C, Lahoti S, Marchina S, Sanan N, Feng W, Kumar S (November 2014). “Acid-suppressive medication use in acute stroke and hospital-acquired pneumonia”. 《Annals of Neurology》 76 (5): 712–718. doi:10.1002/ana.24262. PMC 4214881. PMID 25164323.
Ricketson J, Kimel G, Spence J, Weir R (March 2009). “Acute allergic interstitial nephritis after use of pantoprazole”. 《CMAJ》 180 (5): 535–538. doi:10.1503/cmaj.080456. PMC 2645468. PMID 19255077.
Seifert R (2019). 〈Drugs for Treatment of Gastrointestinal Diseases〉. Seifert R. 《Basic Knowledge of Pharmacology》 (독일어). Cham: Springer International Publishing. 167–180쪽. doi:10.1007/978-3-030-18899-3_13. ISBN 978-3-030-18899-3. S2CID 200109770.
Wolfe MM, Sachs G (February 2000). “Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome”. 《Gastroenterology》 118 (2 Suppl 1): S9–31. doi:10.1016/s0016-5085(00)70004-7. PMID 10868896.
Sachs G, Shin JM, Hunt R (December 2010). “Novel approaches to inhibition of gastric acid secretion”. 《Current Gastroenterology Reports》 12 (6): 437–447. doi:10.1007/s11894-010-0149-5. PMC 2974194. PMID 20924727.
Meyer UA (October 1996). “Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs”. 《European Journal of Gastroenterology & Hepatology》 8 (Suppl 1): S21–S25. doi:10.1097/00042737-199610001-00005. PMID 8930576. S2CID 24171788.

drugs.com

“Pantoprazole Use During Pregnancy”. 《Drugs.com》. 2018년 6월 26일. 2020년 2월 20일에 확인함.
“Pantoprazole Sodium Monograph for Professionals - Drugs.com”. 《Drugs.com》. American Society of Health-System Pharmacists. 2018년 10월 28일에 확인함.

fda.gov

Center for Drug Evaluation and Research. “Postmarket Drug Safety Information for Patients and Providers - FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors”. 《U.S. Food and Drug Administration (FDA)》. 2017년 1월 20일에 원본 문서에서 보존된 문서. 2015년 11월 3일에 확인함.
Center for Drug Evaluation and Research. “Drug Safety and Availability - FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs)”. 《U.S. Food and Drug Administration (FDA)》. 2015년 11월 3일에 확인함.

accessdata.fda.gov

“Pantoprazole: FDA-Approved Drugs”. 《U.S. Food and Drug Administration》. 2020년 8월 15일에 확인함.

medicines.org.uk

“Pantoprazole 20mg gastro-resistant tablets - Summary of Product Characteristics (SmPC)”. 《(emc)》. 2019년 11월 25일. 2020년 2월 20일에 확인함.

nih.gov

ncbi.nlm.nih.gov

Bernshteyn MA, Masood U (2022). 〈Pantoprazole〉. 《StatPearls》. Treasure Island (FL): StatPearls Publishing. PMID 29763120. 2022년 4월 27일에 확인함.
Richardson P, Hawkey CJ, Stack WA (September 1998). “Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders”. 《Drugs》 56 (3): 307–335. doi:10.2165/00003495-199856030-00002. PMID 9777309. S2CID 46962618.
Dammann HG, Fölsch UR, Hahn EG, von Kleist DH, Klör HU, Kirchner T, 외. (March 2000). “Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration”. 《Helicobacter》 5 (1): 41–51. doi:10.1046/j.1523-5378.2000.00006.x. PMID 10672051. S2CID 32184484.
Strand DS, Kim D, Peura DA (January 2017). “25 Years of Proton Pump Inhibitors: A Comprehensive Review”. 《Gut and Liver》 11 (1): 27–37. doi:10.5009/gnl15502. PMC 5221858. PMID 27840364.
Herzig SJ, Doughty C, Lahoti S, Marchina S, Sanan N, Feng W, Kumar S (November 2014). “Acid-suppressive medication use in acute stroke and hospital-acquired pneumonia”. 《Annals of Neurology》 76 (5): 712–718. doi:10.1002/ana.24262. PMC 4214881. PMID 25164323.
Ricketson J, Kimel G, Spence J, Weir R (March 2009). “Acute allergic interstitial nephritis after use of pantoprazole”. 《CMAJ》 180 (5): 535–538. doi:10.1503/cmaj.080456. PMC 2645468. PMID 19255077.
Ahmed A, Clarke JO (2022). 〈Proton Pump Inhibitors (PPI)〉. 《StatPearls》. Treasure Island (FL): StatPearls Publishing. PMID 32491317. 2022년 4월 29일에 확인함.
Wolfe MM, Sachs G (February 2000). “Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome”. 《Gastroenterology》 118 (2 Suppl 1): S9–31. doi:10.1016/s0016-5085(00)70004-7. PMID 10868896.
Sachs G, Shin JM, Hunt R (December 2010). “Novel approaches to inhibition of gastric acid secretion”. 《Current Gastroenterology Reports》 12 (6): 437–447. doi:10.1007/s11894-010-0149-5. PMC 2974194. PMID 20924727.
Meyer UA (October 1996). “Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs”. 《European Journal of Gastroenterology & Hepatology》 8 (Suppl 1): S21–S25. doi:10.1097/00042737-199610001-00005. PMID 8930576. S2CID 24171788.

dailymed.nlm.nih.gov

“Protonix delayed-release- pantoprazole sodium tablet, delayed release Protonix delayed-release- pantoprazole sodium granule, delayed release”. 《DailyMed》. 2019년 5월 2일. 2020년 2월 20일에 확인함.

semanticscholar.org

api.semanticscholar.org

Richardson P, Hawkey CJ, Stack WA (September 1998). “Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders”. 《Drugs》 56 (3): 307–335. doi:10.2165/00003495-199856030-00002. PMID 9777309. S2CID 46962618.
Dammann HG, Fölsch UR, Hahn EG, von Kleist DH, Klör HU, Kirchner T, 외. (March 2000). “Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration”. 《Helicobacter》 5 (1): 41–51. doi:10.1046/j.1523-5378.2000.00006.x. PMID 10672051. S2CID 32184484.
Seifert R (2019). 〈Drugs for Treatment of Gastrointestinal Diseases〉. Seifert R. 《Basic Knowledge of Pharmacology》 (독일어). Cham: Springer International Publishing. 167–180쪽. doi:10.1007/978-3-030-18899-3_13. ISBN 978-3-030-18899-3. S2CID 200109770.
Meyer UA (October 1996). “Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs”. 《European Journal of Gastroenterology & Hepatology》 8 (Suppl 1): S21–S25. doi:10.1097/00042737-199610001-00005. PMID 8930576. S2CID 24171788.

ubc.ca

ti.ubc.ca

“[99] Comparative effectiveness of proton pump inhibitors”. Therapeutics Initiative. 2016년 6월 28일. 2016년 7월 14일에 확인함.

web.archive.org

Center for Drug Evaluation and Research. “Postmarket Drug Safety Information for Patients and Providers - FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors”. 《U.S. Food and Drug Administration (FDA)》. 2017년 1월 20일에 원본 문서에서 보존된 문서. 2015년 11월 3일에 확인함.